DS Healthcare Group (DSKX) vs. The Competition Head to Head Analysis

DS Healthcare Group (OTCMKTS: DSKX) is one of 31 public companies in the “Personal Products” industry, but how does it contrast to its rivals? We will compare DS Healthcare Group to related businesses based on the strength of its valuation, dividends, risk, analyst recommendations, institutional ownership, earnings and profitability.

Volatility & Risk

DS Healthcare Group has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500. Comparatively, DS Healthcare Group’s rivals have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.


This table compares DS Healthcare Group and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DS Healthcare Group -62.31% -1,304.25% -117.85%
DS Healthcare Group Competitors -24.29% 76.69% 1.25%

Analyst Recommendations

This is a summary of recent ratings and target prices for DS Healthcare Group and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DS Healthcare Group 0 0 0 0 N/A
DS Healthcare Group Competitors 365 1275 1536 24 2.38

As a group, “Personal Products” companies have a potential upside of 13.46%. Given DS Healthcare Group’s rivals higher possible upside, analysts plainly believe DS Healthcare Group has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares DS Healthcare Group and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
DS Healthcare Group $12.95 million -$6.93 million 0.00
DS Healthcare Group Competitors $16.34 billion $2.21 billion 402.21

DS Healthcare Group’s rivals have higher revenue and earnings than DS Healthcare Group. DS Healthcare Group is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

0.0% of DS Healthcare Group shares are owned by institutional investors. Comparatively, 56.6% of shares of all “Personal Products” companies are owned by institutional investors. 19.4% of DS Healthcare Group shares are owned by insiders. Comparatively, 15.4% of shares of all “Personal Products” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


DS Healthcare Group rivals beat DS Healthcare Group on 8 of the 9 factors compared.

DS Healthcare Group Company Profile

DS Healthcare Group, Inc., doing business as DS Laboratories, is a personal care, product development and marketing company. The Company develops and markets branded personal care products that address thinning hair conditions, skin care and other personal care needs. It develops technologies and products for hair care and personal care needs. Its technologies include Liposome Technology, which acts as a carrier agent, and is designed to enhance the act ion of the active ingredients in its products, and Nanosome Technology, which acts as a delivery vehicle, and is designed to infuse active compounds into targeted cells. The Company products are primarily sold under its DS Laboratories brand. It also sells certain products under its Polaris Labs and Sigma Skin brands. It markets and sells these products through salons, spas, department stores, specialty retailers and distributors. The Company offers products under three product categories: Hair Care, Skin Care and Personal Care.

Receive News & Ratings for DS Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DS Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply